Dublin, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The "Post-marketing Pharmacovigilance and Medical Information Market by Type by Service, by End-User, and By Region" report has been added to ResearchAndMarkets.com's offering.The global post-marketing pharmacovigilance and medical information market size was estimated to be USD 6.22 billion in 2023 and is expected to reach USD 16.99 billion by 2034 with a CAGR of 9.56% during the forecast period 2024-2034. The market will grow as a result of factors such as rising ...

New modular analytics solution empowers commercial teams to optimize strategies and improve patient outcomes LONDON, Jan. 14, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of DRG Fusion, an innovative platform to support commercial analytics in life sciences. Powered by integrated real-world data and built by clinical and data science experts, Fusion provides biopharma and medtech organizations with the tools to understan ...

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to redefine the future of healthcare. This year, the highly anticipated resource highlights 11 drugs projected to achieve blockbuster status or revolutionize treat ...

LONDON, Dec. 16, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today announced that its Board of Directors (the "Board") authorized a new share repurchase program of up to $500 million of the Company's outstanding ordinary shares through open-market purchases for a period of two years, from January 1, 2025 through December 31, 2026. The new share repurchase program replaces the current share repurchase program which t ...

Faster and more relevant results to empower critical IP decision-making LONDON, Dec. 12, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of AI Search in Derwent™. Combining artificial intelligence (AI) with the premier source of global patent data, Derwent World Patents Index (DWPI)™, this solution will enable intellectual property (IP) professionals to make reliable innovation decisions by finding more relevant patents in ...

Revealing highly active specialties in sciences and social sciencesLONDON, Nov. 27, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, and the Chinese Academy of Sciences (CAS) today released 2024 Research Fronts™, identifying the most dynamic and rapidly growing specialties in sciences and social sciences. This marks the eleventh annual collaboration between the two organizations, with the report launched at a ceremony held in Beijing today.The report ...

文章核心观点 - BioWorld推出新系列“Healing the Health Divide”关注女性健康研究投资不平等问题[1] - 女性占全球人口一半但健康服务不足研究资金少[2] - 2023年只有15%风险投资资金投向女性健康生物制药公司8%公司管线含女性健康资产[3] - 该系列呼吁解决女性健康研究和投资不平等问题[4] 系列相关 - 系列探索性别偏见在研究中的作用女性健康市场潜力等[4] - 包含强调女性健康公平投资等文章[5] - 可通过https://www.bioworld.com/womens_health访问系列[6] BioWorld相关 - 由Clarivate出版全球有作者编辑报道新闻等[7] - 新闻服务自1998年共获61个奖项[7] Clarivate相关 - 是全球变革性情报主要提供商[8] - 在学术政府知识产权和生命科学医疗保健等领域提供服务[8]

核心观点 - Clarivate Plc发布了2024年高被引研究者名单，展示了全球范围内在各自研究领域具有显著和广泛影响力的研究者 [1] 高被引研究者名单概述 - 2024年共有6,636名高被引研究者入选，来自全球59个国家和地区，涵盖1,200多家机构 [2] - 名单基于Web of Science Core Collection™引文索引的数据，并结合ISI™专家的定性分析进行严格评估和筛选 [2] 全球研究人才分布趋势 - 中国大陆和香港特别行政区在高被引研究者数量上取得显著增长，而美国逐渐失去份额，反映出全球顶级科学和学术贡献的地理、政治和文化再平衡 [3] - 美国仍以2,507名高被引研究者位居全球首位，占全球份额的36.4%，但这一份额自2018年以来持续下降 [5] - 中国大陆以1,405名高被引研究者位列第二，占全球份额的20.4%，较2018年翻倍 [5] - 香港特别行政区的高被引研究者数量增至134名，占全球份额的1.9% [5] 研究机构表现 - 中国科学院以308名高被引研究者位居榜首，较去年增加38名 [5] - 哈佛大学、斯坦福大学、清华大学等机构在全球高被引研究者名单中名列前茅 [6] 研究领域和跨领域表现 - 部分研究者被认可在多个Essential Science Indicators™（ESI）研究领域中表现出色，其中216名研究者在两个领域中被提及，22名研究者在三个或更多领域中被提及 [5] 评估和筛选过程 - 评估和筛选过程不断进化，增加了增强过滤器以应对超作者、过度自引、异常引用模式等问题，确保入选研究者符合高被引研究者计划的标准，强调了Clarivate对研究诚信的承诺 [4] - 2024年共颁发了6,886个高被引研究者奖项，其中6,636名是唯一个人，部分研究者因在多个领域的表现而获得多个奖项 [8] 全球研究格局快照 - 全球高被引研究者中，85.4%来自10个国家和地区，74.4%来自前五个国家和地区 [5] - 加州的高被引研究者数量异常集中，达到552名，几乎与英国相当 [5]

文章核心观点 - 中国大陆生物制药行业过去十年迅速发展成为全球创新领导者 Clarivate与中国医药企业协会出版的《十年创新十年展望》报告发布 该报告对国际利益相关者有重要意义[1] 相关目录总结 行业发展成果 - 过去十年中国大陆生物制药行业迅速发展成为全球创新领导者在初始药物推出方面排名前三 受改革投资增加和政策推动行业减少审批时间提高监管标准改善患者获得先进疗法的机会[2] - 中国研发支出在过去十年增长3.5倍超过英国和美国的增长率[2] - 中国医药行业在即将到来的十年将因竞争加剧发生重大变革快速创新和激烈竞争重塑市场动态报告为中国制药公司在未来十年如何优先考虑创新和国际扩张提供思路[3] 报告的意义 - 对全球行业利益相关者是宝贵资源为全球制药公司提供对中国大陆生物制药格局的及时了解包括国际合作机会和加速进入市场的潜力[3] - 为国际投资者跨国制药公司和医疗保健利益相关者提供及时深入的见解帮助他们了解中国大陆在塑造生物制药格局未来方面的作用[5] 报告内容亮点 - 强调中国大陆监管进步药物推出快速增长国内研发作用扩大[3] - 国家医保药品目录通过系统价格谈判降低50 - 60%的成本改善创新药物的可及性[3] - 自2015年以来中国大陆在全球许可和服务交易中的份额从6.5%增长到近9%在关键生命科学领域的研究发表和专利申请方面处于领先地位[3] - 包含影响政策改革医疗可及性和创新投资和研发增长全球一体化和市场机会等关键见解[4] 报告数据来源 - 报告利用全球生命科学社区信任的综合数据和工具包括Cortellis系列工具Web of Science和Derwent Innovation等由Clarivate分析师使用2024年8月31日之前收集的数据编制[6]

Recognizing Roper St. Francis Healthcare, Bon Secours Mercy Health, and Bronson Methodist Hospital for excellence in Physician and Hospital GroupsLONDON, Nov. 13, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, announced the 2023 winners of the Clarivate Healthcare Business Insights™ annual Revenue Cycle Awards. Now in its 12th year, the Revenue Cycle Awards recognize U.S.-based healthcare organizations for exceptional performance on revenue cycle KPI ...